心房颤动患者CA-125表达水平及其意义

doi:10.3969/j.issn.2095-9400.2019.12.011

Abstract
Figure/Table
References (0)
Related Citation (1)

Download: PDF (1520 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To investigate the significance of CA-125 in patients with paroxysmal and persistent atrial fibrillation (AF). Methods: A retrospective study was made of 642 patients admitted to the First Affiliated Hospital of Wenzhou Medical University (China) from June 2017 to June 2018. All subjects enrolled were divided into two groups according to episode/persistent AF and they were compared in paroxysmal AF and persistent AF. Their clinical data (age, gender, BMI, duration of AF, left atrial diameter, ejection fraction, BNP, liver and kidney function, CHA2DS2-VASc score, CA-125, etc.) were analyzed to identify the risk factors of persistent AF by multivariate regression analysis. Results: Statistical regression results showed that patients with persistent AF had higher levels of CA-125 (P<0.001) compared with patients with paroxysmal AF. Logistic regression analyses showed that CA-125 levels appeared to be unaffected by age, LAD, ejection fraction, sex and so on. Conclusion: Patients with persistent AF have higher CA-125 level.

Key words： CA-125 paroxysmal atrial fibrillation persistent atrial fibrillation atrial remodeling

Received: 09 May 2019

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CHEN Chen
	HU Xiaokang
	WANG Kaijing
	HUANG Zhouqing

URL:

https://xb.wmu.edu.cn/EN/10.3969/j.issn.2095-9400.2019.12.011 OR https://xb.wmu.edu.cn/EN/Y2019/V49/I12/910

[1] CHUGH S S, HAVMOELLER R, NARAYANAN K, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study[J]. Circulation, 2014, 129(8): 837-847.
[2] BALL J, CARRINGTON M J, MCMURRAY J J, et al. Atrial fibrillation: profile and burden of an evolving epidemic in the 21st century[J]. Int J Cardiol, 2013, 167(5): 1807-1824.
[3] JALIFE J, KAUR K. Atrial remodeling, fibrosis, and atrial fibrillation[J]. Trends Cardiovasc Med, 2015, 25(6): 475-484.
[4] ROLDÁN V, MARÍN F, MARTÍNEZ J G, et al. Relation of interleukin-6 levels and prothrombin fragment 1+2 to a point-based score for stroke risk in atrial fibrillation[J]. Am J Cardiol, 2005, 95(7): 881-882.
[5] BARBIERI R L, NILOFF J M, BAST R C, et al. Elevated serum concentrations of CA-125 in patients with advanced endometriosis[J]. Fertil Steril, 1986, 45(5): 630-634.
[6] BIDART J M, THUILLIER F, AUGEREAU C, et al. Kinetics of serum tumor marker concentrations and usefulness in clinical monitoring[J]. Clin Chem, 1999, 45(10): 1695-1707.
[7] HUNG C L, HUNG T C, LIU C C, et al. Relation of carbohydrate antigen-125 to left atrial remodeling and its prognostic usefulness in patients with heart failure and preserved left ventricular ejection fraction in women[J]. Am J Cardiol, 2012, 110(7): 993-1000.
[8] SEKIGUCHI H, SHIMAMOTO K, TAKANO M, et al. Cancer antigen-125 plasma level as a biomarker of new-onset atrial fibrillation in postmenopausal women[J]. Heart, 2016, 103(17): 1368-1373.
[9] 黄从新, 张澍, 黄德嘉, 等. 心房颤动: 目前的认识和治疗建议(2018)[J]. 中华心律失常学杂志, 2018, 22(4): 279-346.
[10] HOLDENRIEDER S, MOLINA R, GION M, et al. Alternative antibody for the detection of CA125 antigen: a European multicenter study for the evaluation of the analytical and clinical performance of the Access OV Monitor assay on the UniCel Dxl 800 Immunoassay System[J]. Clin Chem Lab Med, 2008, 46(5): 588-599.
[11] YAGMUR E, DRIESCH R, GRESSNER A M, et al. Technical evaluation of the Beckman Coulter OV-Monitor (CA 125 antigen) immunoassay[J]. Clin Chem Lab Med, 2006, 44(4): 420-422.
[12] Casaclang-Verzosa G, Gersh B J, Tsang T S. Structural and functional remodeling of the left atrium: clinical and therapeutic implications for atrial fibrillation[J]. J Am Coll Cardiol, 2008, 51(1): 1-11.
[13] NATTEL S, BURSTEIN B, DOBREV D. Atrial remodeling and atrial fibrillation: mechanisms and implications[J]. Circ Arrhythm Electrophysiol, 2008, 1(1): 62-73.
[14] NATTEL S, HARADA M. Atrial remodeling and atrial fibrillation: recent advances and translational perspectives[J]. J Am Coll Cardiol, 2014, 63(22): 2335-2345.
[15] THOMAS L, ABHAYARATNA W P. Left atrial reverse remodeling: mechanisms, evaluation, and clinical significance [J]. JACC Cardiovasc Imaging, 2017, 10(1): 65-77.
[16] O’BRIEN T J, TANIMOTO H, KONISHI I, et al. More than 15 years of CA 125: what is known about the antigen, its structure and its function[J]. Int J Biol Markers, 1998, 13(4): 188-195.
[17] ZEILLEMAKER A M, VERBRUGH H A, HOYNCK VAN PAPENDRECHT A A, et al. CA 125 secretion by peritoneal mesothelial cells[J]. J Clin Path, 1994, 47(3): 263-265.
[18] NÚÑEZ J, NÚÑEZ E, CONSUEGRA L, et al. Carbohydrate antigen 125: an emerging prognostic risk factor in acute heart failure?[J]. Heart, 2007, 93(6): 716-721.
[19] NÚÑEZ J, SANCHIS J, BODÍ V, et al. Improvement in risk stratification with the combination of the tumour marker antigen carbohydrate 125 and brain natriuretic peptide in patients with acute heart failure[J]. Eur Heart J, 2010, 31(14): 1752-1763.
[20] D’ALOIA A, FAGGIANO P, AURIGEMMA G, et al. Serum levels of carbohydrate antigen 125 in patients with chronic heart failure[J]. J Am Coll Cardiol, 2003, 41(10): 1805-1811.
[21] YUCEL H, KAYA H, ZORLU A, et al. Cancer antigen 125 levels and increased risk of new-onset atrial fibrillation[J]. Herz, 2014, 40 Suppl 2: 119-124.
[22] STANCIU A E, STANCIU M M, VATASESCU R G. NT-proBNP and CA 125 levels are associated with increased pro-inflammatory cytokines in coronary sinus serum of patients with chronic heart failure[J]. Cytokine, 2018, 111: 13-11119.
[23] HARADA M, VAN WAGONER D R, NATTEL S. Role of inflammation in atrial fibrillation pathophysiology and man-agement[J]. Circ J, 2015, 79(3): 495-502.
[24] 郑建雷, 严沛元, 王海清. 非瓣膜性心房颤动与脑梗死的相关因素分析[J]. 温州医科大学学报, 2014, 44(1): 44-47.
[25] BULLER R E, BERMAN M L, BLOSS J D, et al. CA 125 regression: a model for epithelial ovarian cancer response[J]. Am J Obstet Gynecol, 1991, 165(2): 360-367.